FIELD: organic chemistry and pharmaceuticals.
SUBSTANCE: group of inventions is aimed at the treatment of diseases associated with DGAT2. The following is disclosed: a compound of formula I, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein A, B and E are each independently CH and N; D is either N, CH or C-halo-C1-C7 alkyl; R1 represents C1-C7 alkyl, C3-C10 cycloalkyl or halogen-C1-C7 alkyl; R2 represents hydrogen or C1-C7 alkyl; R3 represents -G-J-L; G represents -NH- or a direct chemical bond; J represents C1-C7 alkylene, C2-C7 alkenylene, C1-C7 alkylene-C6-C10 arylene, C1-C7 alkylene-amino-C6-C10 arylene, C1-C7 alkylene-C6-C10 -aryloxylene-C1-C7 alkylene, C1-C7 alkylene-C3-C10 cycloalkyl, C2-C7 alkenylene-C3-C10 cycloalkyl, C1-C7 alkoxylene-C6-C10 arylene, C6-C10 arylene, C3-C10 cycloalkyl, C6-C10 arylene-C1-C7 alkylene, 5-12-membered heterocycloalkylene, 5-12- membered heterocycloalkylene-C6-C10 arylene or 5-12 membered heterocycloalkylene-5-12 membered heteroarylene; L represents hydrogen, halogen, nitro, carboxy (-COOH), aminocarbonyl-C1-C7 alkyl, carboxy-C1-C7 alkyl, carboxy -C1-C7 alkoxy, carboxy-C1-C7 alkyl -C6-C10 aryl, C3-C10 cycloalkyl, C6-C10 aryl, C6-C10 aryloxy, 5-12 membered heterocycloalkyl or 5-12 membered heteroaryl; or R2 and R3 together with the nitrogen atom to which they are attached can form a 5-12 membered heterocycloalkyl; alkyl, alkylene, alkylene-arylene, alkenyl, alkenylene, cycloalkyl, carboxyalkyl, carboxyalkoxy, alkoxyalkyl, aminocarbonyl, aryl, aryl-alkyl, arylene, aryloxy, heterocycloalkyl or heteroaryl optionally substituted with 1-4 substituents selected from hydroxy, halogen, oxo, nitro, -COOH, -CH2COOH, C1-C7 alkyl, methylidene, C2-C7 alkenyl, C1-C7 alkoxy, halogen-C1-C7 alkyl, C1-C7 alkylsulphonyl, C1-C7 alkylcarbonyl, C1-C7 alkoxycarbonyl and 5-12-membered heteroaryle-C1-C7 alkyl; heterocycloalkylene, heterocycloalkyl, heteroarylene or heteroaryl includes from 1 to 5 heteroatoms, selected from N, O and S. Besides, the following is disclosed: a pharmaceutical composition containing a compound of formula (I), a pharmaceutical composition for the treatment of diseases associated with DGAT2, containing a compound of formula (I).
EFFECT: group of inventions provides effective treatment of diseases mediated by diacylglycerol O-acyltransferase 2 (DGAT2).
4 cl, 1 tbl, 130 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW BIARYL DERIVATIVE USED AS INHIBITOR OF DIACYLGLYCEROL ACYLTRANSFERASE 2 AND ITS USE | 2021 |
|
RU2808433C1 |
| NEW AMINOARYL DERIVATIVE SUITABLE AS A DIACYLGLYCEROLACYL TRANSFERASE 2 INHIBITOR AND ITS APPLICATION | 2020 |
|
RU2799819C1 |
| NOVEL COMPOUND EXHIBITING ENTEROPEPTIDASE INHIBITING ACTIVITY | 2019 |
|
RU2768755C1 |
| COMPOUND FOR DESTRUCTION OF ANDROGEN RECEPTOR AND ITS PHARMACEUTICAL USE THEREOF | 2021 |
|
RU2817356C1 |
| COMPOUND CONTAINING OXADIAZOLE AND A PHARMACEUTICAL COMPOSITION CONTAINING IT | 2019 |
|
RU2789456C2 |
| INDOLE AND INDAZOLE COMPOUNDS AS CELLULAR NECROSIS INHIBITORS | 2008 |
|
RU2437883C1 |
| INDOLE AND INDAZOLE DERIVATIVES SHOWING PRESERVING ACTION ON CELLS, TISSUES AND ORGANS | 2009 |
|
RU2460525C2 |
| BIARYL DERIVATIVE AS GPR120 AGONIST | 2015 |
|
RU2683648C2 |
| NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF | 2021 |
|
RU2817736C1 |
| INDOLE COMPOUNDS AS CELL NECROSIS INHIBITORS | 2008 |
|
RU2477282C2 |
